TD Cowen 46th Annual Health Care Conference March 2, 2026 10:30 AM ESTCompany ParticipantsBrett Monia - Founder, ...

Detailed price information for Ionis Pharmaceuticals (IONS-Q) from The Globe and Mail including charting and trades.

Oppenheimer 36th Annual Healthcare Life Sciences Conference February 26, 2026 12:00 PM ESTCompany ParticipantsBrett ...

Detailed price information for Ionis Pharmaceuticals (IONS-Q) from The Globe and Mail including charting and trades.

In recent weeks, Ionis Pharmaceuticals announced that the FDA accepted a Priority Review for olezarsen in severe hypertriglyceridemia, released 2026 revenue guidance of US$800 million to US$825 ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) on Tuesday released topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG). sHTG is a condition ...

On Tuesday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Ono Pharmaceutical Co., Ltd entered into a license agreement in which Ono obtains exclusive global rights for the development and ...

Thursday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Biogen Inc (NASDAQ:BIIB) decided to terminate the development of BIIB105 (ION541), an investigational antisense oligonucleotide (ASO) for ...

CARLSBAD, Calif. & OSAKA, Japan--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have entered into a license ...

TRYNGOLZA® generated $108 million in net product sales in 2025, the first year of launch –- Olezarsen sHTG launch preparations on track, sNDA submitted -- Exceeded 2025 financial guidance, 2026 ...

CEO Brett Monia told investors at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference that the company received FDA acceptance of its supplemental NDA for olezarsen in severe ...

CARLSBAD, Calif. (AP) — CARLSBAD, Calif. (AP) — Ionis Pharmaceuticals Inc. (IONS) on Wednesday reported a loss of $229 million in its fourth quarter. On a per-share basis, the Carlsbad, ...